Alterity Therapeutics Ltd. filings document a foreign private issuer and development-stage biotechnology company focused on disease-modifying treatments for neurodegenerative diseases. Its Form 6-K reports provide current updates on the company’s Multiple System Atrophy program, including ATH434, the bioMUSE Natural History Study, quantitative MRI biomarker research, medical meeting presentations, and clinical or regulatory program activity.
The filing record also includes Appendix 4C quarterly cash-flow and corporate activity reports, exhibits incorporated by reference into Form S-8 and Form F-3 registration statements, governance updates, and notices related to securities matters such as consolidation or split activity. These filings describe the company’s operating progress, financing framework, board and management disclosures, risk-related development context, and capital-structure records.
Alterity Therapeutics Chief Financial Officer Abby Sarah Macnish Niven filed an initial ownership report detailing indirect equity interests in the company held through CASAM Investments Pty Ltd.
The filing lists 454,545 ordinary shares and a listed option expiring on 26 Feb 2027 over 151,510 underlying ordinary shares at an exercise price of 0.0280 per share. These entries describe existing indirect holdings rather than new market purchases or sales.
Alterity Therapeutics reported positive regulatory progress for its lead drug ATH434 in Multiple System Atrophy (MSA). After a Type C Meeting, the FDA provided written feedback supporting the company’s clinical pharmacology and non-clinical plans for a planned Phase 3 pivotal trial.
The company now aims to secure FDA agreement on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, with an End-of-Phase 2 meeting targeted for mid-year 2026. ATH434 has already shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and additional positive data in an open-label Phase 2 study in advanced MSA, and Alterity is preparing to initiate Phase 3.
Alterity Therapeutics Limited has reported a proposed issue of 150,000,000 options as payment for services to Lawrence Gozlan and Chairman Julian Babarczy. The options have an exercise price of A$0.02 and expire five years after issue, with an expected expiry date of 26/6/2031.
The options are to be issued for non-cash consideration, with each option exercisable into one fully paid ordinary share. The proposed issue date is 26/6/2026 and is subject to shareholder approval at a meeting scheduled for 27/5/2026 under ASX Listing Rule 7.1.
Alterity Therapeutics Limited has filed a Form 6-K highlighting its planned participation in the Bell Potter Healthcare Horizons Summit in Sorrento, Australia on 12-13 March 2026. CEO David Stamler, M.D. will join a fireside chat on optimising late-stage clinical trials and hold 1-on-1 investor meetings.
The company is a clinical-stage biotechnology business developing disease-modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. Its lead candidate, ATH434, has shown clinically meaningful efficacy in a Phase 2 trial and positive results in an open-label Phase 2 study, and the company is preparing a Phase 3 pivotal trial in MSA.
Alterity Therapeutics filed a Form 6-K to disclose the appointment of Daniel O. Claassen, M.D., M.S. as Chief Medical Advisor beginning in March 2026. Dr. Claassen is a tenured professor of neurology at Vanderbilt University Medical Center and an internationally recognized expert in neurodegenerative diseases, especially movement disorders and multiple system atrophy (MSA).
He previously served as coordinating investigator for Alterity’s Phase 2 study of its lead drug candidate ATH434 in MSA and has led numerous clinical trials across academia and industry. Alterity highlights that ATH434 showed clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open-label Phase 2 study in advanced MSA, and notes it is preparing a Phase 3 pivotal trial.
Alterity Therapeutics Limited reports its Q2 FY26 cash flow and a corporate update centered on lead candidate ATH434 for Multiple System Atrophy (MSA). The company highlights strengthened Phase 2 data, a Fast Track designation from the U.S. FDA, and active planning for an End-of-Phase 2 meeting targeted for mid-2026 to shape a pivotal Phase 3 trial.
New analyses of Phase 2 data showed an improved efficacy signal for the 75 mg dose on a modified UMSARS Part I endpoint and a beneficial effect on orthostatic hypotension symptoms. Alterity also points to a potential commercial opportunity of US$2.4 billion for ATH434 in MSA and is advancing partnering discussions with multiple pharmaceutical companies.
As of 31 December 2025, Alterity held A$49.2 million in cash and cash equivalents, with quarterly operating cash outflows of A$5.28 million, implying an estimated 9.3 quarters of funding. The company strengthened governance with a new Chair, added board representation for the CEO, and expanded its leadership team to support late-stage development and strategic partnering.
Alterity Therapeutics provides a shareholder update highlighting major progress with its lead drug candidate ATH434 for Multiple System Atrophy (MSA) and outlining priorities for 2026. In 2025 the company completed its Phase 2 program in MSA, reporting “resoundingly favourable” results, with ATH434 shown to be safe and well-tolerated and to provide strong signals of efficacy, including slowing disease progression and improving mobility and orthostatic hypotension, with no drug-related serious or severe adverse events compared with placebo. Alterity is now planning a pivotal Phase 3 program in MSA and expects to hold an End-of-Phase 2 meeting with the FDA in mid-2026 to finalize the Phase 3 trial design. The company also reports governance and leadership enhancements, including appointing Julian Babarczy as Chair of the Board and expanding its management team in investor relations and corporate strategy to support potential future commercialization and increased business development.